z-logo
Premium
Cancer transcriptomic profiling from rapidly enriched circulating tumor cells
Author(s) -
Morrison Gareth J.,
Cunha Alexander T.,
Jojo Nita,
Xu Yucheng,
Xu Yili,
Kwok Eric,
Robinson Peggy,
Dorff Tanya,
Quinn David,
Carpten John,
Manojlovic Zarko,
Goldkorn Amir
Publication year - 2020
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.32915
Subject(s) - transcriptome , prostate cancer , circulating tumor cell , gene expression profiling , liquid biopsy , cancer research , cancer , computational biology , medicine , biology , metastasis , bioinformatics , gene , gene expression , biochemistry
Transcriptomic profiling of metastatic cancer can illuminate mechanisms of progression and lead to new therapies, but standard biopsy is invasive and reflects only a single metastatic site. In contrast, circulating tumor cell (CTC) profiling is noninvasive and repeatable, reflecting the dynamic and systemic nature of advanced disease. To date, transcriptomic profiling of CTCs has not delivered on its full potential, because white blood cells (WBCs) vastly outnumber CTCs. Current profiling strategies either lack cancer sensitivity and specificity or require specialized CTC capture protocols that are not readily scalable to large patient cohorts. Here, we describe a new strategy for rapid CTC enrichment and transcriptomic profiling using commercially available WBC depletion, microfluidic enrichment and RNA sequencing. When applied to blood samples from patients with advanced prostate cancer (PC), transcriptomes from enriched samples cluster with cancer positive controls and previously undetectable prostate‐specific transcripts become readily measurable. Gene set enrichment analysis reveals multiple significantly enriched signaling pathways associated with PC, as well as novel pathways that merit further study. This accessible and scalable approach yields cancer‐specific transcriptomic data and can be applied repeatedly and noninvasively in large cancer patient cohorts to discover new therapeutic targets in advanced disease.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here